Cambridge Healthtech Institute’s 5th Annual
Preclinical and Translational Immuno-Oncology
Predictive Preclinical Models and Translational Strategies for Cancer Immunotherapy
August 11-12, 2020
The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the
need for predictive preclinical models and translational strategies to understand combination immunotherapy, study responses and resistance to cancer immunotherapy, and identify novel biomarkers and targets. Please join Cambridge Healthtech Institute’s
Fifth Annual Preclinical and Translational Immuno-Oncology meeting and learn about new clinically-relevant models for screening IO therapies and translational strategies to support clinical IO programs.
Preliminary Agenda
Translatability of Preclinical Models in Immuno-Oncology Drug Discovery
Mithun Khattar, PhD, Scientist II, Immuno-Oncology Lead, Takeda Oncology
Efficacy Testing and Mechanistic Studies in Patient-Derived Microtumor/Immune Cell Models
Christophe Sachse, PhD, Site Head Berlin, NMI TT Pharmaservices
Talk Title to be Announced
Zhao Chen, PhD, Lab Head, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research
Independent Contributions Account for Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies
Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs
How a Blood-Clotting Protein and Blood Platelets Promote Immune Evasion, Cancer Progression
Zihai Li, MD, Founding Director, Pelotonia Institute for Immuno-Oncology; Professor, Translational Therapeutics Program, Internal Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
Deciphering the Function of B Cells in Human Cancer
Tullia C. Bruno, PhD, Assistant Professor, Immunology, University of Pittsburgh & Hillman Cancer Center
Talk Title to be Announced
Cara Haymaker, PhD, Assistant Professor; Director, Oncology Research and Immuno-Monitoring Core (ORION), Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Long-Term Outcomes and Responses to Retreatment in Melanoma Patients Treated with PD-1 Blockade
Allison Betof Warner, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
PD-1 Antibodies Either as Monotherapy or Precision Medicine Informed Combinations are Transforming Cancer Care
Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories
New Immune Checkpoints: From Discoveries to Clinical Trials
XingXing Zang, PhD, Professor and Louis Goldstein Swan Chair, Albert Einstein College of Medicine
TIM-3 Antibody for Immuno-Oncology
Xiaomo Jiang, PhD, Principle Scientist II, Immuno-Oncology, Novartis Institutes for BioMedical Research
Preclinical Identification and Validation of Immuno-Oncology Targets
Marcus Bosenberg, MD, PhD, Professor of Dermatology, Pathology, and Immunobiology; Interim Director, Yale Center for Immuno-Oncology; Director, Center for Precision Cancer Modeling, Yale University
For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com